The S&P 500 fell 0.1% on Tuesday, July 8, 2025, after President Trump extended the deadline for "reciprocal" tariffs and ...

Shares of Moderna surged 9.5% on Tuesday to $32.75 in a notable reversal of recent bearish sentiment, buoyed by legal ...

Moderna’s cash flow issues are more immediate than those of its peers, so the new provision could have a greater impact on ...

From Oslo’s Munch Museum to little-visited Colombo treasures, be sure to add these fascinating spaces to your itinerary ...

Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage” of the revenue generated by Spikevax ...

The Moderna vaccine is one of the vaccines currently available in the United States and other countries to protect against COVID-19, which is the disease the novel coronavirus causes.

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.

(Reuters) -Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group ...

(RTTNews) - Moderna Inc. (MRNA) announced that the U.S. Food and Drug Administration has approved its respiratory syncytial virus (RSV) vaccine, mRESVIA (mRNA-1345), for preventing lower ...